Related Experiment Video
Updated: Aug 5, 2026
Quantitative Polymerase Chain Reaction (qPCR)-Based Rapid Diagnosis of Helicobacter pylori Infection and Antibiotic Resistance
Published on: July 28, 2023
Vonoprazan-based dual and quadruple therapy with varying duration for Helicobacter pylori eradication: A multicenter,
Kunping Ju1, Hanyue Zhao1, Leina Guo2
1Department of Gastroenterology, Qilu Hospital of Shandong University, Jinan, Shandong, China; Shandong Provincial Clinical Research Center for digestive disease, Shandong, China; Laboratory of Translational Gastroenterology, Qilu Hospital of Shandong University, Jinan, Shandong, China; Robot engineering laboratory for precise diagnosis and therapy of GI tumor, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Objectives:
The study was conducted to assess the effectiveness and safety of two simplified dual and quadruple therapies compared with the guideline-recommended 14-day dual therapy for first-line Helicobacter pylori treatment.
Methods:
This randomised controlled trial (RCT) enrolled treatment-naïve patients across six clinical centres. The study randomly allocated participants equally to one of three regimens: VA-14 (vonoprazan 20 mg twice daily and amoxicillin 1000 mg three times daily for 14 days), VA-10 (same drugs with VA-14 but for 10 days), and VBAT-7 (vonoprazan 20 mg twice daily, tetracycline 500 mg three times daily, amoxicillin 1000 mg twice daily, and bismuth potassium citrate 220 mg twice daily for 7 days). The 13C-urea breath test was conducted to confirm eradication at least six weeks after treatment.
Results:
Out of 387 patients who were eligible, 330 were assigned randomly. The VBAT-7 group exhibited non-inferior efficacy to the VA-14 group, with the eradication rates of 90.0% (99/110) and 91.8% (101/110) in intention-to-treat (ITT) analysis (P = 0.017), 92.5% (99/107) and 94.4% (101/107) in modified ITT analysis (P = 0.008), and 93.3% (98/105) and 95.2% (100/105) in per-protocol (PP) analysis (P = 0.006). However, the non-inferiority of efficacy between VA-10 and VA-14 was not established. The groups did not show significant variations in adverse events or compliance.
Conclusions:
VBAT-7 demonstrated non-inferiority to VA-14 and represents a potential first-line option for first-line H. pylori treatment. The VA-10 regimen achieved acceptable eradication in PP analysis but did not statistically meet the non-inferiority criterion.
Trial Registration:
ClinicalTrials.gov ID: NCT06723197.
Related Concept Videos
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
01:13Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
01:28Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
01:25Peptic Ulcer Disease III: Clinical Manifestations and Complications